Literature DB >> 16910369

Understanding and treating kleptomania: new models and new treatments.

Jon E Grant1.   

Abstract

Kleptomania, characterized by repetitive, uncontrollable stealing of items not needed for personal use, is a disabling disorder that often goes unrecognized in clinical practice. Although originally conceptualized as an obsessive compulsive spectrum disorder, emerging evidence (clinical characteristics, familial transmission, and treatment response) suggests that kleptomania may have important similarities to both addictive and mood disorders. In particular, kleptomania frequently co-occurs with substance use disorders, and it is common for individuals with kleptomania to have first-degree relatives who suffer from a substance use disorder. Additionally, there is some suggestion that selective serotonin reuptake inhibitors, the treatment of choice for obsessive compulsive disorder, may lack efficacy for kleptomania. Instead, other medications (lithium, anti-epileptics, and opioid antagonists) have shown early promise in treating kleptomania. Evidence suggests that there may be subtypes of kleptomania that are more like OCD, whereas others have more similarities to addictive and mood disorders. Subtyping of individuals with kleptomania may be a useful way to better understand this behavior and decide on effective treatment interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16910369

Source DB:  PubMed          Journal:  Isr J Psychiatry Relat Sci        ISSN: 0333-7308            Impact factor:   0.481


  3 in total

1.  Kleptomania and potential exacerbating factors: a review and case report.

Authors:  Farid Ramzi Talih
Journal:  Innov Clin Neurosci       Date:  2011-10

2.  Pathological stealing in dementia: poor response to SSRI medications.

Authors:  Mario F Mendez
Journal:  J Clin Psychiatry       Date:  2011-03       Impact factor: 4.384

Review 3.  Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention.

Authors:  Angelo Antonini; Roberto Cilia
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.